BACKGROUND: In a previous study, morphometry and multivariate cluster analysis was performed on 97 lesions. These consisted of atypical adenomatous hyperplasia (AAH), considered to be an important lesion corresponding to a step of carcinogenesis for adenocarcinoma of the human lung, Clara cell type, and type 2 pneumocyte type adenocarcinomas. Although AAH and the two types of adenocarcinoma were re-classified into three clusters and AAH was defined in clear morphologic terms, the biologic nature of AAH has yet to be clarified. In the present study, immunohistochemical analysis was performed to gain a deeper understanding of the relationship between AAH and the two types of adenocarcinoma, and to compare the results with those obtained by morphometry. METHODS: The 97 lesions analyzed by morphometry were submitted to immunohistochemical analyses using antibodies against surfactant apoprotein A, urine protein 1, carcinoembryonic antigen and cytochrome P-450s (1A1-2, 2B1-2, 2E1). Also examined, as controls, were 17 lesions with adenomatous hyperplasia (AH), a non-neoplastic reactive change of bronchiolo-alveolar cells, 30 areas of normal Clara cells, and 36 areas of normal type 2 pneumocytes. The immunoreactivity was graded by introducing a semi-quantitative scoring system. RESULTS: Immunohistochemically, AAHs behaved quite similarly to the lesions classified as Clara cell type or type 2 pneumocyte type adenocarcinomas. For any of the antibodies employed, no significant difference in immunoreactivity was demonstrated among these lesions. CONCLUSIONS: The results suggest, in accordance with our previous morphometry, that AAH is a lesion closely related with Clara cell type and type 2 pneumocyte type adenocarcinomas, probably as their common precursor. However, the two types of adenocarcinomas, despite their characteristic morphologic features, are indistinguishable using the biological indicators applied in this study.
BACKGROUND: In a previous study, morphometry and multivariate cluster analysis was performed on 97 lesions. These consisted of atypical adenomatous hyperplasia (AAH), considered to be an important lesion corresponding to a step of carcinogenesis for adenocarcinoma of the human lung, Clara cell type, and type 2 pneumocyte type adenocarcinomas. Although AAH and the two types of adenocarcinoma were re-classified into three clusters and AAH was defined in clear morphologic terms, the biologic nature of AAH has yet to be clarified. In the present study, immunohistochemical analysis was performed to gain a deeper understanding of the relationship between AAH and the two types of adenocarcinoma, and to compare the results with those obtained by morphometry. METHODS: The 97 lesions analyzed by morphometry were submitted to immunohistochemical analyses using antibodies against surfactant apoprotein A, urine protein 1, carcinoembryonic antigen and cytochrome P-450s (1A1-2, 2B1-2, 2E1). Also examined, as controls, were 17 lesions with adenomatous hyperplasia (AH), a non-neoplastic reactive change of bronchiolo-alveolar cells, 30 areas of normal Clara cells, and 36 areas of normal type 2 pneumocytes. The immunoreactivity was graded by introducing a semi-quantitative scoring system. RESULTS: Immunohistochemically, AAHs behaved quite similarly to the lesions classified as Clara cell type or type 2 pneumocyte type adenocarcinomas. For any of the antibodies employed, no significant difference in immunoreactivity was demonstrated among these lesions. CONCLUSIONS: The results suggest, in accordance with our previous morphometry, that AAH is a lesion closely related with Clara cell type and type 2 pneumocyte type adenocarcinomas, probably as their common precursor. However, the two types of adenocarcinomas, despite their characteristic morphologic features, are indistinguishable using the biological indicators applied in this study.
Authors: A Sally Davis; Daniel S Chertow; Jenna E Moyer; Jon Suzich; Aline Sandouk; David W Dorward; Carolea Logun; James H Shelhamer; Jeffery K Taubenberger Journal: J Histochem Cytochem Date: 2015-01-20 Impact factor: 2.479
Authors: H Kanazawa; M Ebina; N Ino-Oka; M Shimizukawa; T Takahashi; S Fujimura; T Imai; T Nukiwa Journal: Am J Pathol Date: 2000-04 Impact factor: 4.307
Authors: Kentaro Iwanaga; Yanan Yang; Maria Gabriela Raso; Lijiang Ma; Amy E Hanna; Nishan Thilaganathan; Seyed Moghaddam; Christopher M Evans; Huaiguang Li; Wei-Wen Cai; Mitsuo Sato; John D Minna; Hong Wu; Chad J Creighton; Francesco J Demayo; Ignacio I Wistuba; Jonathan M Kurie Journal: Cancer Res Date: 2008-02-15 Impact factor: 12.701
Authors: Don L Gibbons; Wei Lin; Chad J Creighton; Zain H Rizvi; Philip A Gregory; Gregory J Goodall; Nishan Thilaganathan; Liqin Du; Yiqun Zhang; Alexander Pertsemlidis; Jonathan M Kurie Journal: Genes Dev Date: 2009-09-15 Impact factor: 11.361
Authors: Hyun Ju Lee; Jin Mo Goo; Chang Hyun Lee; Chul-Gyu Yoo; Young Tae Kim; Jung-Gi Im Journal: Korean J Radiol Date: 2007 Jan-Feb Impact factor: 3.500